Antibody-drug conjugates hitting this target abound.
ApexOnco Front Page
Recent articles
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
At least 15 dual-payload ADCs will be discussed.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Ikena, Senti and others look to clinical presentations at AACR.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
